GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Ltd (FRA:IQI) » Definitions » Debt-to-Asset

Incannex Healthcare (FRA:IQI) Debt-to-Asset : 0.02 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Incannex Healthcare Debt-to-Asset?

Incannex Healthcare's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.15 Mil. Incannex Healthcare's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.23 Mil. Incannex Healthcare's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €15.87 Mil. Incannex Healthcare's debt to asset for the quarter that ended in Mar. 2024 was 0.02.


Incannex Healthcare Debt-to-Asset Historical Data

The historical data trend for Incannex Healthcare's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incannex Healthcare Debt-to-Asset Chart

Incannex Healthcare Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.13 - - -

Incannex Healthcare Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.01 - 0.02 0.02

Competitive Comparison of Incannex Healthcare's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Incannex Healthcare's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incannex Healthcare's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Incannex Healthcare's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Incannex Healthcare's Debt-to-Asset falls into.



Incannex Healthcare Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Incannex Healthcare's Debt-to-Asset for the fiscal year that ended in Jun. 2022 is calculated as

Incannex Healthcare's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incannex Healthcare  (FRA:IQI) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Incannex Healthcare Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Incannex Healthcare's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Incannex Healthcare (FRA:IQI) Business Description

Traded in Other Exchanges
Address
8 Century Circuit Norwest, Suite 105, Sydney, NSW, AUS, 3000
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products.